296 related articles for article (PubMed ID: 25379018)
41. RAS, BRAF, and TP53 gene mutations in Taiwanese colorectal cancer patients.
Chang YS; Chang SJ; Yeh KT; Lin TH; Chang JG
Onkologie; 2013; 36(12):719-24. PubMed ID: 24356563
[TBL] [Abstract][Full Text] [Related]
42. KRAS mutation associated with CD44/CD166 immunoexpression as predictors of worse outcome in metastatic colon cancer.
Ribeiro KB; da Silva Zanetti J; Ribeiro-Silva A; Rapatoni L; de Oliveira HF; da Cunha Tirapelli DP; Garcia SB; Feres O; da Rocha JJ; Peria FM
Cancer Biomark; 2016 Mar; 16(4):513-21. PubMed ID: 27062566
[TBL] [Abstract][Full Text] [Related]
43. Oncosuppressor methylation: a possible key role in colon metastatic progression.
Tommasi S; Pinto R; Petriella D; Pilato B; Lacalamita R; Santini D; Zito F; Colucci G; Paradiso A; Silvestris N
J Cell Physiol; 2011 Jul; 226(7):1934-9. PubMed ID: 21506124
[TBL] [Abstract][Full Text] [Related]
44. Relative contribution of normal and neoplastic cells determines telomerase activity and telomere length in primary cancers of the prostate, colon, and sarcoma.
Engelhardt M; Albanell J; Drullinsky P; Han W; Guillem J; Scher HI; Reuter V; Moore MA
Clin Cancer Res; 1997 Oct; 3(10):1849-57. PubMed ID: 9815573
[TBL] [Abstract][Full Text] [Related]
45. Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases.
Barault L; Charon-Barra C; Jooste V; de la Vega MF; Martin L; Roignot P; Rat P; Bouvier AM; Laurent-Puig P; Faivre J; Chapusot C; Piard F
Cancer Res; 2008 Oct; 68(20):8541-6. PubMed ID: 18922929
[TBL] [Abstract][Full Text] [Related]
46. KRAS mutation is associated with lung metastasis in patients with curatively resected colorectal cancer.
Tie J; Lipton L; Desai J; Gibbs P; Jorissen RN; Christie M; Drummond KJ; Thomson BN; Usatoff V; Evans PM; Pick AW; Knight S; Carne PW; Berry R; Polglase A; McMurrick P; Zhao Q; Busam D; Strausberg RL; Domingo E; Tomlinson IP; Midgley R; Kerr D; Sieber OM
Clin Cancer Res; 2011 Mar; 17(5):1122-30. PubMed ID: 21239505
[TBL] [Abstract][Full Text] [Related]
47. Microsatellite instability-low colorectal cancer acquires a KRAS mutation during the progression from Dukes' A to Dukes' B.
Asaka S; Arai Y; Nishimura Y; Yamaguchi K; Ishikubo T; Yatsuoka T; Tanaka Y; Akagi K
Carcinogenesis; 2009 Mar; 30(3):494-9. PubMed ID: 19147861
[TBL] [Abstract][Full Text] [Related]
48. Rare oncogenic mutations of predictive markers for targeted therapy in triple-negative breast cancer.
Grob TJ; Heilenkötter U; Geist S; Paluchowski P; Wilke C; Jaenicke F; Quaas A; Wilczak W; Choschzick M; Sauter G; Lebeau A
Breast Cancer Res Treat; 2012 Jul; 134(2):561-7. PubMed ID: 22610646
[TBL] [Abstract][Full Text] [Related]
49. Suppressor of Ty homolog-5, a novel tumor-specific human telomerase reverse transcriptase promoter-binding protein and activator in colon cancer cells.
Chen R; Zhu J; Dong Y; He C; Hu X
Oncotarget; 2015 Oct; 6(32):32841-55. PubMed ID: 26418880
[TBL] [Abstract][Full Text] [Related]
50. Prognostic value of TP53, KRAS and EGFR mutations in nonsmall cell lung cancer: the EUELC cohort.
Scoccianti C; Vesin A; Martel G; Olivier M; Brambilla E; Timsit JF; Tavecchio L; Brambilla C; Field JK; Hainaut P;
Eur Respir J; 2012 Jul; 40(1):177-84. PubMed ID: 22267755
[TBL] [Abstract][Full Text] [Related]
51. Target Genetic Abnormalities for the Treatment of Colon Cancer and Its Progression to Metastasis.
Baviskar T; Momin M; Liu J; Guo B; Bhatt L
Curr Drug Targets; 2021; 22(7):722-733. PubMed ID: 33213339
[TBL] [Abstract][Full Text] [Related]
52. Relationship between telomere shortening, genetic instability, and site of tumour origin in colorectal cancers.
Rampazzo E; Bertorelle R; Serra L; Terrin L; Candiotto C; Pucciarelli S; Del Bianco P; Nitti D; De Rossi A
Br J Cancer; 2010 Apr; 102(8):1300-5. PubMed ID: 20386541
[TBL] [Abstract][Full Text] [Related]
53. Expression of Genes Associated with Telomere Homeostasis in TP53 Mutant LoVo Cell Lines as a Model for Genomic Instability.
Samassekou O; Bastien N; Yan J; Mai S; Drouin R
Methods Mol Biol; 2018; 1769():253-262. PubMed ID: 29564829
[TBL] [Abstract][Full Text] [Related]
54. Telomerase-deficient mice with short telomeres are resistant to skin tumorigenesis.
González-Suárez E; Samper E; Flores JM; Blasco MA
Nat Genet; 2000 Sep; 26(1):114-7. PubMed ID: 10973262
[TBL] [Abstract][Full Text] [Related]
55. Systematic analysis of telomere length and somatic alterations in 31 cancer types.
Barthel FP; Wei W; Tang M; Martinez-Ledesma E; Hu X; Amin SB; Akdemir KC; Seth S; Song X; Wang Q; Lichtenberg T; Hu J; Zhang J; Zheng S; Verhaak RG
Nat Genet; 2017 Mar; 49(3):349-357. PubMed ID: 28135248
[TBL] [Abstract][Full Text] [Related]
56. Onset of Telomere Dysfunction and Fusions in Human Ovarian Carcinoma.
Huda N; Xu Y; Bates AM; Rankin DA; Kannan N; Gilley D
Cells; 2019 May; 8(5):. PubMed ID: 31060240
[TBL] [Abstract][Full Text] [Related]
57. Shorter telomeres and high telomerase activity correlate with a highly aggressive phenotype in breast cancer cell lines.
Ceja-Rangel HA; Sánchez-Suárez P; Castellanos-Juárez E; Peñaroja-Flores R; Arenas-Aranda DJ; Gariglio P; Benítez-Bribiesca L
Tumour Biol; 2016 Sep; 37(9):11917-11926. PubMed ID: 27072825
[TBL] [Abstract][Full Text] [Related]
58. The complex intratumoral heterogeneity of colon cancer highlighted by laser microdissection.
Buob D; Fauvel H; Buisine MP; Truant S; Mariette C; Porchet N; Wacrenier A; Copin MC; Leteurtre E
Dig Dis Sci; 2012 May; 57(5):1271-80. PubMed ID: 22198706
[TBL] [Abstract][Full Text] [Related]
59.
Watanabe S; Tsuchiya K; Nishimura R; Shirasaki T; Katsukura N; Hibiya S; Okamoto R; Nakamura T; Watanabe M
Mol Cancer Res; 2019 Jul; 17(7):1459-1467. PubMed ID: 30988165
[TBL] [Abstract][Full Text] [Related]
60. Expression profile of telomere-associated genes in multiple myeloma.
Díaz de la Guardia R; Catalina P; Panero J; Elosua C; Pulgarin A; López MB; Ayllón V; Ligero G; Slavutsky I; Leone PE
J Cell Mol Med; 2012 Dec; 16(12):3009-21. PubMed ID: 22947336
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
